• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical oncology >Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer
【24h】

Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer

机译：晚期前列腺癌首次诊断时的化学疗法-革命还是进化？从英国泌尿肿瘤学团体英国调查中发现的结果，以评估肿瘤学家对一线多西紫杉醇联合雄激素剥夺疗法联合治疗去势敏感的转移性和高危/局部晚期前列腺癌的观点

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: There have been three randomised trials investigating docetaxel in combination with androgen deprivation therapy as first-line therapy for hormone-sensitive metastatic and locally advanced/high-risk prostate cancer. The largest of these studies, UK STAMPEDE trial, recently presented in June 2015. The aim of this survey was to evaluate if oncologists' practice has changed as a result of these studies, or if their practice is likely to change in different clinical settings in the future.
机译：目的：已有三项随机试验研究多西他赛联合雄激素剥夺疗法作为激素敏感性转移性和局部晚期/高危前列腺癌的一线治疗。这些研究中最大的一项研究是最近在2015年6月提交的UK STAMPEDE试验。该调查的目的是评估这些研究是否改变了肿瘤科医生的执业，或者他们的执业可能在不同的临床环境中发生变化。未来。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号